naratuximab emtansine 
GtoPdb Ligand ID: 9949
|
Synonyms: IMGN-529 | IMGN529 | K7153A-SMCC-DM1
Compound class:
Antibody
Comment: Naratuximab emtansine (IMGN529) is a CD37- targeting antibody drug conjugate carrying a potent anti-mitotic agent (maytansinoid DM1) payload. This ADC is being investigated for clinical efficacy as a treatment for B cell malignancies, with empahsis on diffuse large B cell lymphoma (DLBCL) in light of preliminary results from the phase 1 clinical trial NCT01534715 [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Naratuximab emtansine is an early phase clinical lead for the treatment of B cell lymphomas [4]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Diffuse large B-cell lymphoma |
Disease Ontology:
DOID:0050745 |
Naratuximab emtansine is an EMA and FDA orphan drug that may be used to treat patients with DLBCL. | 2-3 |
| B-cell non-hodgkin lymphoma |
Orphanet:
ORPHA171915 |
Naratuximab emtansine has completed Phase 1 clinical evaluation in patients with relapsed or refractory B-cell non-Hodgkin lymphoma- see NCT01534715. | 4 |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License